Patients without antiphospholipid syndrome should receive a DOAC. DOACs are preferred over vitamin K antagonists such as warfarin/coumadin.
From the 2019 ASH guideline:
![](https://www.thebloodproject.com/wp-content/uploads/2022/06/image-23.png)
![](https://www.thebloodproject.com/wp-content/uploads/2022/06/image-24.png)
2021 ACCP clinical guideline recommendations:
![](https://www.thebloodproject.com/wp-content/uploads/2022/06/image-33.png)
![](https://www.thebloodproject.com/wp-content/uploads/2022/06/image-34.png)
![](https://www.thebloodproject.com/wp-content/uploads/2022/06/image-35.png)
Oct
6
2021
Patients without antiphospholipid syndrome should receive a DOAC. DOACs are preferred over vitamin K antagonists such as warfarin/coumadin.
From the 2019 ASH guideline:
2021 ACCP clinical guideline recommendations: